These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9638977)

  • 1. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma.
    Kato H; Kinoshita T; Suzuki S; Nagasaka T; Hatano S; Murate T; Saito H; Hotta T
    Leuk Lymphoma; 1998 Mar; 29(1-2):71-9. PubMed ID: 9638977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).
    Jones EA; Pringle JH; Angel CA; Rees RC
    Leuk Lymphoma; 2002 Jun; 43(6):1313-21. PubMed ID: 12153001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines in malignant lymphomas: review and prospective evaluation.
    Hsu SM; Waldron JW; Hsu PL; Hough AJ
    Hum Pathol; 1993 Oct; 24(10):1040-57. PubMed ID: 8406414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma.
    Feldmann G; Nischalke HD; Nattermann J; Banas B; Berg T; Teschendorf C; Schmiegel W; Dührsen U; Halangk J; Iwan A; Sauerbruch T; Caselmann WH; Spengler U
    Clin Cancer Res; 2006 Aug; 12(15):4491-8. PubMed ID: 16899594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration.
    Kato H; Kinoshita T; Suzuki S; Nagasaka T; Murate T; Saito H; Hotta T
    Br J Haematol; 1996 Mar; 92(4):1014-21. PubMed ID: 8616061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunohistochemical in situ demonstration of cytokines in Hodgkin and non-Hodgkin lymphoma].
    Müller H; Takeshita M; Krause J; Schuster K; Kikuchi M; Stutte HJ
    Verh Dtsch Ges Pathol; 1992; 76():164-8. PubMed ID: 1283251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-10 in non-Hodgkin's lymphoma.
    Cortes J; Kurzrock R
    Leuk Lymphoma; 1997 Jul; 26(3-4):251-9. PubMed ID: 9322887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines.
    Hugo F; Dittmar T; Treutler EK; Zänker KS; Kuehn JJ
    Onkologie; 2005 Aug; 28(8-9):415-20. PubMed ID: 16160404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
    Voorzanger N; Touitou R; Garcia E; Delecluse HJ; Rousset F; Joab I; Favrot MC; Blay JY
    Cancer Res; 1996 Dec; 56(23):5499-505. PubMed ID: 8968107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.
    Merz H; Fliedner A; Orscheschek K; Binder T; Sebald W; Müller-Hermelink HK; Feller AC
    Am J Pathol; 1991 Nov; 139(5):1173-80. PubMed ID: 1951632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine and paracrine functions of cytokines in malignant lymphomas.
    Hsu SM; Hsu PL
    Biomed Pharmacother; 1994; 48(10):433-44. PubMed ID: 7858153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
    Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
    Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Bhatt S; Sarosiek KA; Lossos IS
    Leuk Lymphoma; 2017 Jan; 58(1):17-29. PubMed ID: 27405876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Alas S; Bonavida B
    Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas.
    Ford R; Tamayo A; Martin B; Niu K; Claypool K; Cabanillas F; Ambrus J
    Blood; 1995 Jul; 86(1):283-93. PubMed ID: 7795235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Cytokine Levels Assist in the Diagnosis of Respiratory Bacterial Infections or Concurrent Bacteremia in Patients With Non-Hodgkin's Lymphoma.
    Zhang L; Zhang J; He H; Ling X; Li F; Yang Z; Zhao J; Li H; Yang T; Zhao S; Shi K; Guan X; Zhao R; Li Z
    Front Cell Infect Microbiol; 2022; 12():860526. PubMed ID: 35463642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.